Abstract
High-temperature-requirement A2 (HtrA2)/Omi/PARK13 is a serine protease with extensive homology to the Escherichia coli HtrAs that are required for bacterial survival at high temperatures. The HtrA2 protein is a key modulator of mitochondrial molecular quality control but under stressful conditions it is released into the cytosol, where it promotes cell death by various pathways, including caspase-dependent pathway and ER stress-mediated apoptosis. Recently, the HtrA2 protein has received great attention for its potential role in neurodegeneration. Here, we review the current knowledge and pathophysiological functions of the HtrA2 protein in neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease.
Keywords: Alzheimer's disease, apoptosis, HtrA2, HtrA2 interacting proteins, mitochondria, Parkinson’s disease, protein quality control.
Graphical Abstract
Current Protein & Peptide Science
Title:Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
Volume: 18 Issue: 7
Author(s): Hui-Gwan Goo, Hyangshuk Rhim and Seongman Kang*
Affiliation:
- Division of Life Sciences, Korea University, 1, 5ka, Anam-dong, Sungbuk-gu, Seoul 136-701,Korea
Keywords: Alzheimer's disease, apoptosis, HtrA2, HtrA2 interacting proteins, mitochondria, Parkinson’s disease, protein quality control.
Abstract: High-temperature-requirement A2 (HtrA2)/Omi/PARK13 is a serine protease with extensive homology to the Escherichia coli HtrAs that are required for bacterial survival at high temperatures. The HtrA2 protein is a key modulator of mitochondrial molecular quality control but under stressful conditions it is released into the cytosol, where it promotes cell death by various pathways, including caspase-dependent pathway and ER stress-mediated apoptosis. Recently, the HtrA2 protein has received great attention for its potential role in neurodegeneration. Here, we review the current knowledge and pathophysiological functions of the HtrA2 protein in neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Goo Hui-Gwan, Rhim Hyangshuk and Kang Seongman*, Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases, Current Protein & Peptide Science 2017; 18 (7) . https://dx.doi.org/10.2174/1389203717666160311115750
DOI https://dx.doi.org/10.2174/1389203717666160311115750 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design In Silico Methods for Predicting Ligand Binding Determinants of Cytochromes P450
Current Topics in Medicinal Chemistry Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry NBS1 Heterozygosity and Cancer Risk
Current Genomics DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Nanoparticles in Gastric Cancer Management
Current Pharmaceutical Design Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Current Medicinal Chemistry Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs
Current Pharmaceutical Design Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry New Perspectives in the Treatment of Cushings Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The DREAM of Pain Relief
Current Rheumatology Reviews Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia
Current Molecular Medicine Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Withdrawal Notice: Preparation and Applications of Glyconanoparticles
Current Drug Targets Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Current Pharmaceutical Design Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds